Paper Details
- Home
- Paper Details
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
Author: ChenChien-Hung, HsuChing-Sheng, HsuYu-Chun, HuiYee Tak, KanYee-Man, LiMichael K K, LiuChen-Hua, LiuKevin S H, TsaiMing-Chang, WongGrace L H, YapDesmond Y H, YuMing-Lung, YuenMan-Fung
Original Abstract of the Article :
Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641551/
データ提供：米国国立医学図書館（NLM）
Glecaprevir/Pibrentasvir: Treatment of Chronic Hepatitis C in Patients with Severe Renal Impairment
Chronic hepatitis C virus (HCV) infection is a major public health concern, with millions of people worldwide affected. This study investigates the efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB), a direct-acting antiviral agent, in treating chronic HCV infection in Asian patients with severe renal impairment. The researchers conducted a study to evaluate the treatment outcomes and side effects of GLE/PIB in this patient population. Their findings suggest that GLE/PIB is a safe and effective treatment option for chronic HCV infection in patients with severe renal impairment, providing valuable information for clinicians managing this patient population.
Navigating the Desert of Hepatitis C: A Promising Treatment for Patients with Renal Impairment
This study offers hope for patients with chronic HCV infection and severe renal impairment. The finding that GLE/PIB is a safe and effective treatment option for this patient population is encouraging news, providing a new path to cure for those battling both HCV and renal disease. This research is like a camel caravan, traversing the vast desert of HCV treatment, seeking to provide relief and healing for all.
A New Oasis of Hope for HCV Patients: GLE/PIB and Renal Impairment
This research provides valuable insights into the treatment of chronic HCV infection in patients with severe renal impairment. The findings suggest that GLE/PIB is a safe and effective treatment option, offering a new and promising approach to manage this challenging condition. It's like a desert oasis, providing relief and hope for patients seeking a cure for HCV, even in the presence of renal impairment.
Dr.Camel's Conclusion
This study offers encouraging news for patients with chronic hepatitis C and severe renal impairment. The findings suggest that glecaprevir/pibrentasvir is a safe and effective treatment option for this challenging patient population. This research is like a beacon of hope in the vast desert of HCV treatment, guiding us towards a brighter future for patients with both HCV and renal impairment.
Date :
- Date Completed 2021-09-16
- Date Revised 2021-09-16
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.